Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Significant Increase in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 96,254 shares, an increase of 257.5% from the June 15th total of 26,924 shares. Based on an average daily volume of 110,311 shares, the short-interest ratio is currently 0.9 days. Approximately 0.3% of the shares of the company are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP bought a new position in Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 9.05% of the company’s stock.

Dogwood Therapeutics Price Performance

Shares of NASDAQ DWTX opened at $1.42 on Monday. The stock has a market cap of $47.75 million, a P/E ratio of -0.13 and a beta of 1.70. The firm’s 50-day simple moving average is $1.61 and its 200 day simple moving average is $2.36. Dogwood Therapeutics has a fifty-two week low of $1.28 and a fifty-two week high of $9.50.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its earnings results on Thursday, May 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. On average, sell-side analysts anticipate that Dogwood Therapeutics will post -0.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on DWTX shares. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Dogwood Therapeutics in a research report on Tuesday, May 19th. Weiss Ratings lowered Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $12.00.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.